Literature DB >> 3133317

Inhibition of human lymphocyte proliferation and cleavage of interleukin-2 by Pseudomonas aeruginosa proteases.

T G Theander1, A Kharazmi, B K Pedersen, L D Christensen, N Tvede, L K Poulsen, N Odum, M Svenson, K Bendtzen.   

Abstract

This study was undertaken to determine the effect of Pseudomonas aeruginosa alkaline protease (AP) and elastase (ELA) on human lymphocyte function. AP at 50 micrograms/ml and ELA at 12 micrograms/ml caused a 50% inhibition of phytohemagglutinin-induced proliferation. There was no difference in the effect of proteases on CD4- and CD8-positive cells. To determine the effect of proteases on interleukin-2 (IL-2)-induced cell proliferation, the proteases and IL-2 were added to the IL-2-dependent CTLL-2 cell line. AP and ELA inhibited the proliferation of these cells. When IL-2 was added in excess, the inhibition was partly reversed. ELA at 10 micrograms/ml cleaved IL-2, as judged by size chromatography of a reaction mixture containing 125I-labeled IL-2 and the proteases. The ELA-digested IL-2 exhibited a reduced binding capacity to IL-2 receptors on the lymphocytes. Furthermore, treatment of phytohemagglutinin-stimulated lymphocytes with AP and ELA resulted in inhibition of binding of intact IL-2 to IL-2 receptors on the stimulated lymphocytes. These results indicated that P. aeruginosa-derived enzymes are able to interfere with human lymphocyte function in vitro and that this effect might be due to cleavage of IL-2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133317      PMCID: PMC259461          DOI: 10.1128/iai.56.7.1673-1677.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Selective modulation of the CD4 molecular complex by Pseudomonas aeruginosa alkaline protease and elastase.

Authors:  B K Pedersen; A Kharazmi; T G Theander; N Odum; V Andersen; K Bendtzen
Journal:  Scand J Immunol       Date:  1987-07       Impact factor: 3.487

2.  Antigenic specificities of Pseudomonas aeruginosa alkaline protease and elastase defined by human T cell clones.

Authors:  M J Parmely; R T Horvat
Journal:  J Immunol       Date:  1986-08-01       Impact factor: 5.422

3.  Serogroups of Pseudomonas aeruginosa and the immune response of patients with cystic fibrosis.

Authors:  E Diaz; L L Mosovich; E Neter
Journal:  J Infect Dis       Date:  1970-03       Impact factor: 5.226

4.  Inhibition of human natural killer cell activity by Pseudomonas aeruginosa alkaline protease and elastase.

Authors:  B K Pedersen; A Kharazmi
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

5.  Variables which affect suppression of the immune response induced by Pseudomonas aeruginosa exotoxin A.

Authors:  P S Holt; M L Misfeldt
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

6.  Suppression of the delayed-type hypersensitivity and cell-mediated immune responses to Listeria monocytogenes induced by Pseudomonas aeruginosa.

Authors:  L L Blackwood; T Lin; J I Rowe
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

7.  Effect of Pseudomonas aeruginosa proteases on human leukocyte phagocytosis and bactericidal activity.

Authors:  A Kharazmi; H O Eriksen; G Döring; W Goldstein; N Høiby
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1986-10

8.  Suppression of cellular immunity to Listeria monocytogenes by activated macrophages: mediation by prostaglandins.

Authors:  J C Petit; G Richard; B Burghoffer; G L Daguet
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

9.  Decreased delayed-type hypersensitivity and increased protection to Listeria monocytogenes seen in mice infected with mucoid and nonmucoid Pseudomonas aeruginosa.

Authors:  L L Blackwood
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

10.  Identification of the principal T lymphocyte-stimulating antigens of Pseudomonas aeruginosa.

Authors:  M J Parmely; B H Iglewski; R T Horvat
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 2.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

3.  Inhibitory and stimulatory effects of Pseudomonas aeruginosa pyocyanine on human T and B lymphocytes and human monocytes.

Authors:  A J Ulmer; J Pryjma; Z Tarnok; M Ernst; H D Flad
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

Review 4.  Bacterial perturbation of cytokine networks.

Authors:  M Wilson; R Seymour; B Henderson
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 5.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

6.  Inhibition of human natural killer cell activity by Legionella pneumophila protease.

Authors:  C Rechnitzer; M Diamant; B K Pedersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-11       Impact factor: 3.267

7.  Proteolytic inactivation of cytokines by Pseudomonas aeruginosa.

Authors:  M Parmely; A Gale; M Clabaugh; R Horvat; W W Zhou
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

Review 8.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

9.  Legionella pneumophila protease inactivates interleukin-2 and cleaves CD4 on human T cells.

Authors:  C S Mintz; R D Miller; N S Gutgsell; T Malek
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

10.  Enzymic and permeability activity of Pseudomonas aeruginosa after treatment with sub-MICs of organic ammonium salts.

Authors:  A Hostacká; V Majtán
Journal:  Folia Microbiol (Praha)       Date:  1994       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.